Ocugen, Inc (OCGN)

Currency in USD
1.215
-0.025(-2.02%)
Real-time Data·
OCGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1801.240
52 wk Range
0.5151.900
Key Statistics
Prev. Close
1.24
Open
1.18
Day's Range
1.18-1.24
52 wk Range
0.515-1.9
Volume
2.41M
Average Volume (3m)
4.6M
1-Year Change
27.86%
Book Value / Share
0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OCGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.000
Upside
+640.74%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Ocugen, Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Ocugen, Inc Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Ocugen, Inc Earnings Call Summary for Q3/2025

  • Ocugen missed Q3 2025 revenue forecast of $400,000, yet stock rose 5.59% to $1.51 in premarket trading, suggesting investor confidence in gene therapy pipeline.
  • Company reported $32.9 million in cash reserves, bolstered by a $20 million direct offering, with total operating expenses of $19.4 million for the quarter.
  • CEO highlighted progress of lead candidate OCU400 for retinitis pigmentosa, with plans to submit a rolling BLA in H1 2026 and commercialization targeted for 2027.
  • Strategic partnership with Kwang Dong Pharmaceutical for South Korean market demonstrates global expansion efforts amid advancement of gene therapy portfolio.
  • Management expressed optimism about closing 2025 'on a strong note' with catalysts expected in early 2026, despite ongoing high R&D expenditures.
Last Updated: 05/11/2025, 15:24
Read Full Transcript

Compare OCGN to Peers and Sector

Metrics to compare
OCGN
Peers
Sector
Relationship
P/E Ratio
−6.0x−1.8x−0.6x
PEG Ratio
0.52−0.090.00
Price/Book
108.3x1.8x2.6x
Price / LTM Sales
71.2x7.9x3.3x
Upside (Analyst Target)
-94.0%41.3%
Fair Value Upside
Unlock9.3%4.9%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.000
(+640.74% Upside)

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.07 / -0.056
Revenue / Forecast
1.75M / 400.00K
EPS Revisions
Last 90 days

OCGN Income Statement

People Also Watch

4.485
LAC
-2.50%
58.28
MP
+1.29%
1.100
BYND
+8.91%
564.74
APP
+1.54%
2.320
PLUG
-6.83%

FAQ

What Is the Ocugen (OCGN) Premarket Price Today?

The Ocugen (OCGN) premarket price is 1.180. Premarket price change units: -0.060. Premarket percentage change: -4.840%. Premarket volume: 154,670.000. Current date: 14 Nov 2025. Previous close: 1.240

What Stock Exchange Does Ocugen Trade On?

Ocugen is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Ocugen?

The stock symbol for Ocugen is "OCGN."

What Is the Ocugen (OCGN) Afterhours Price Today? (Afterhours variable test: 1.240) Current Date: 14 Nov 2025

After hours price: 1.240. After hours price change (units): 0.000. Price change percentage: 0.000%

What Is the Ocugen Market Cap?

As of today, Ocugen market cap is 380.09M.

What Is Ocugen's Earnings Per Share (TTM)?

The Ocugen EPS (TTM) is -0.22.

When Is the Next Ocugen Earnings Date?

Ocugen will release its next earnings report on 26 Mar 2026.

From a Technical Analysis Perspective, Is OCGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Ocugen Stock Split?

Ocugen has split 1 times.

How Many Employees Does Ocugen Have?

Ocugen has 95 employees.

What is the current trading status of Ocugen (OCGN)?

As of 14 Nov 2025, Ocugen (OCGN) is trading at a price of 1.215, with a previous close of 1.240. The stock has fluctuated within a day range of 1.180 to 1.240, while its 52-week range spans from 0.515 to 1.900.

What Is Ocugen (OCGN) Price Target According to Analysts?

The average 12-month price target for Ocugen is USD9, with a high estimate of USD15 and a low estimate of USD7. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +640.74% Upside potential.

What Is the OCGN Premarket Price?

OCGN's last pre-market stock price is 1.180. The pre-market share volume is 154,670.000, and the stock has decreased by -0.060, or -4.840%.

What Is the OCGN After Hours Price?

OCGN's last after hours stock price is 1.240, the stock has decreased by 0.000, or 0.000%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.